UK Cannabis Policy History: From 1928 to Now

UK Cannabis Policy History: From 1928 to Now

The United Kingdom’s relationship with cannabis has undergone dramatic shifts over nearly a century. From legal accessibility to strict prohibition, and now to carefully controlled medical use, understanding this history is essential for patients and healthcare professionals navigating today’s regulatory landscape. This article traces the evolution of UK cannabis law and its impact on medical practice and patient access.

The Early Years: 1928 to 1970

Cannabis was largely unregulated in the United Kingdom until the 1920s. The turning point came in 1928 when cannabis was added to the Schedule of the Dangerous Drugs Act 1920, following international pressure and Britain’s commitment to the Geneva Conventions on narcotic drugs. This action moved cannabis from an ordinary pharmaceutical ingredient to a controlled substance, effectively removing it from legitimate medical use within a few years.

Prior to this ban, cannabis-based preparations were available through pharmacies and prescribed by doctors for conditions including pain, sleep disturbances, and spasticity. The shift to prohibition was driven more by international treaty obligations and growing social concerns about recreational use than by scientific evidence of harm. By the mid-20th century, cannabis had virtually disappeared from the British medical pharmacopoeia.

The 1960s and 1970s saw cannabis primarily discussed in the context of recreational use and criminal justice. Medical applications were largely forgotten, and research into therapeutic potential was minimal. The Misuse of Drugs Act 1971 cemented cannabis as a Schedule B controlled drug (later reclassified to Schedule I in 2008), with no recognised medical use under UK law.

The Long Prohibition Era: 1970 to 2017

For nearly five decades, cannabis remained completely off-limits for medical use in the United Kingdom. During this period, patients with conditions that might have benefited from cannabis treatments—including epilepsy, chronic pain, and multiple sclerosis—had no legal option to access it. Meanwhile, medical research elsewhere in the world, particularly in Canada and parts of the United States, began accumulating evidence of cannabis’s therapeutic potential.

This era saw a disconnect between emerging scientific evidence and UK policy. International research published in peer-reviewed journals documented cannabinoids’ potential for conditions like chemotherapy-induced nausea, neuropathic pain, and severe epilepsy. However, the UK remained bound by its Schedule I classification, which assumed no medical value and restricted research. Some UK researchers managed to conduct limited studies with special licences, but clinical application remained impossible.

The prohibition was also justified by concerns about cannabis’s side effects, potential for dependence, and the lack of standardised pharmaceutical formulations. These were legitimate regulatory concerns, but they created a circular problem: without medical access and research, evidence could not be gathered that might justify changing the rules.

The Turning Point: 2017 and Beyond

The landscape began to shift following high-profile cases, particularly that of Billy Caldwell in 2017 and 2018. A young boy with severe intractable epilepsy, Caldwell’s condition had not responded to conventional treatments. When his mother obtained cannabis oil and reported significant seizure reduction, subsequent temporary confiscation of the medication sparked public and political outcry. This case, along with others, prompted a comprehensive review.

In November 2018, the UK government announced that cannabis-derived medicinal products would be rescheduled from Schedule I to Schedule II, recognising that they could have medical value when prescribed by specialist doctors. This was a watershed moment. The decision was based on advice from the Advisory Council on the Misuse of Drugs (ACMD) and recognised the emerging evidence base, particularly for epilepsy, multiple sclerosis, and cancer-related symptoms.

In November 2018, the Medicines and Healthcare products Regulatory Agency (MHRA) began accepting applications for cannabis-derived medicinal products. This meant that manufacturers could now seek marketing authorisation for cannabis-based medicines using the standard pharmaceutical regulatory pathway, provided they could demonstrate safety and efficacy.

Current Medical Cannabis Framework in the UK

Today, medical cannabis UK is regulated under a strict framework designed to balance therapeutic potential with safety and quality control. The National Institute for Health and Care Excellence (NICE) has published guidance on cannabis-based medicinal products for specific conditions, including:

• Chronic pain (particularly neuropathic pain)
• Treatment-resistant epilepsy
• Spasticity associated with multiple sclerosis
• Chemotherapy-induced nausea and vomiting

Currently, there are limited MHRA-approved cannabis-derived medicines available on the NHS. Sativex (nabiximols) is approved for MS-related spasticity, and Epidyolex (cannabidiol) is approved for certain severe epilepsy forms. However, access remains restricted, and many patients must pursue private prescriptions through specialised clinics.

The MHRA continues to evaluate new cannabis-derived products. For medicines not yet licensed, specialist NHS consultants may prescribe “unlicensed” cannabis-based products under specific circumstances, following the guidelines established after the 2018 policy change. This typically requires documented treatment resistance to conventional therapies.

Several initiatives have aimed to support evidence-gathering, including Project Twenty21 (a medical cannabis registry allowing doctors to prescribe and collect real-world data) and the Medical Cannabis Registry. These endeavours help build the evidence base that regulators and clinicians need.

What This Means for UK Patients Today

For patients seeking medical cannabis, the current environment is more accessible than at any point since the 1920s, but it remains significantly restricted compared to many other jurisdictions. Access depends on several factors: the specific condition, whether you meet NICE guidance criteria, your NHS trust’s prescribing policies, and your ability to access specialist services.

Private clinics offering medical cannabis consultations have emerged across the UK, though costs can be substantial—estimated between £150 to £500+ per consultation, with ongoing medication costs varying widely. NHS access remains limited, though some specialist NHS clinics do prescribe cannabis-based medicines within their regional commissioning arrangements.

Patients must understand that cannabis-based medicines remain controlled drugs, subject to prescription requirements, pharmacist dispensing restrictions, and the same driving-impairment regulations as other medications. Legal access through prescription is distinct from the broader criminal cannabis prohibition, which remains in place for non-medical use.

The regulatory framework is still evolving. The MHRA’s approval pathways, NICE’s guidance updates, and NHS commissioning decisions continue to develop as evidence accumulates. Patients and clinicians should consult current resources from the MHRA, NICE, and their local NHS commissioning bodies for the most up-to-date information.

Frequently Asked Questions

Is medical cannabis legal in the UK?

Yes, cannabis-derived medicinal products are legal when prescribed by a registered specialist doctor and obtained through licensed pharmacies. However, cannabis remains a controlled drug, and only certain products and conditions qualify under current MHRA and NICE guidance. Non-medical use remains illegal.

Can I get medical cannabis through the NHS?

NHS prescribing of cannabis-based medicines is possible but limited. It typically requires meeting strict criteria, such as those outlined in NICE guidance, and may depend on your local NHS trust’s prescribing policy. Many patients pursue private prescriptions through specialist clinics, though this incurs significant costs.

What conditions qualify for medical cannabis treatment in the UK?

NICE guidance recognises potential benefits for treatment-resistant epilepsy, spasticity related to multiple sclerosis, chronic pain (particularly neuropathic pain), and chemotherapy-induced nausea and vomiting. However, the specific criteria and availability vary, and clinical assessment by a specialist is required to determine individual suitability.

How to Get a Cannabis Prescription